
PetIQ PETQ
Annual report 2023
added 02-29-2024
PetIQ Book Value 2011-2026 | PETQ
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value PetIQ
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 868 M | 819 M | 820 M | 294 M | 328 M | 321 M | 105 M | 41 M | 46.3 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 868 M | 41 M | 405 M |
Quarterly Book Value PetIQ
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 857 M | - | 792 M | 855 M | 924 M | 820 M | 827 M | 843 M | 853 M | 772 M | 772 M | 772 M | 772 M | 673 M | 673 M | 673 M | 673 M | 495 M | 495 M | 495 M | 495 M | 141 M | 141 M | 141 M | 141 M | 81.3 M | 81.3 M | - | - | 92.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 924 M | 81.3 M | 568 M |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | ||
|
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | ||
|
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M | ||
|
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | ||
|
Canopy Growth Corporation
CGC
|
487 M | $ 1.1 | 2.84 % | $ 118 M | ||
|
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | ||
|
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
1.71 B | $ 2.64 | 1.35 % | $ 1.38 B | ||
|
Evolus
EOLS
|
-23.1 M | $ 5.68 | 37.53 % | $ 366 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
7.75 M | $ 0.59 | 6.08 % | $ 10.3 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 3.81 | -16.81 % | $ 53.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | ||
|
Harrow Health
HROW
|
52.1 M | $ 40.02 | 3.65 % | $ 1.47 B | ||
|
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
609 M | $ 3.65 | 4.89 % | $ 86.3 M | ||
|
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | ||
|
Emergent BioSolutions
EBS
|
649 M | $ 8.95 | 0.39 % | $ 458 M | ||
|
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | ||
|
Assertio Holdings
ASRT
|
138 M | $ 12.19 | 2.48 % | $ 866 M | ||
|
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
-82 M | $ 5.67 | -0.87 % | $ 2.07 B | ||
|
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | ||
|
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | ||
|
Organogenesis Holdings
ORGO
|
385 M | $ 2.87 | 0.01 % | $ 378 M | ||
|
OrganiGram Holdings
OGI
|
306 M | $ 1.4 | 2.19 % | $ 402 M | ||
|
Rockwell Medical
RMTI
|
21.3 M | $ 0.91 | 1.03 % | $ 21.2 M | ||
|
Perrigo Company plc
PRGO
|
2.94 B | $ 11.71 | 2.81 % | $ 1.62 B | ||
|
Sundial Growers
SNDL
|
1.13 B | $ 1.55 | 1.21 % | $ 3.37 M | ||
|
TherapeuticsMD
TXMD
|
29.3 M | $ 2.25 | 1.35 % | $ 23.5 M | ||
|
Veru
VERU
|
32.3 M | $ 2.53 | 0.4 % | $ 341 M | ||
|
Viatris
VTRS
|
21.1 B | $ 14.74 | -1.04 % | $ 17.7 B | ||
|
Pacira BioSciences
PCRX
|
778 M | $ 22.92 | 3.69 % | $ 1.06 B | ||
|
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
85.4 M | $ 4.79 | 2.57 % | $ 144 M | ||
|
cbdMD
YCBD
|
1.96 M | $ 0.75 | -2.76 % | $ 3.23 M | ||
|
SCYNEXIS
SCYX
|
73 M | $ 0.76 | 1.22 % | $ 36.4 M | ||
|
Solid Biosciences
SLDB
|
137 M | $ 6.14 | 3.02 % | $ 251 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 2.74 | -0.36 % | $ 3.4 M | ||
|
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
3.33 B | $ 7.33 | -0.48 % | $ 4.53 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M |